Ryan Deschner
Stock Analyst at Raymond James
(4.83)
# 72
Out of 5,090 analysts
19
Total ratings
83.33%
Success rate
49.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Upgrades: Strong Buy | $92 → $143 | $97.73 | +46.33% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $4.35 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $34.31 | +19.50% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $13.44 | +100.97% | 3 | Aug 8, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $5.78 | +107.61% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $23.70 | +110.97% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $38.53 | +216.64% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $9.80 | +185.71% | 3 | Jan 14, 2025 |
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92 → $143
Current: $97.73
Upside: +46.33%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.35
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $34.31
Upside: +19.50%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $13.44
Upside: +100.97%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $5.78
Upside: +107.61%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $23.70
Upside: +110.97%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $38.53
Upside: +216.64%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $9.80
Upside: +185.71%